DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%... Show more
DVA moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 35 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 66 cases where DVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
DVA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on DVA as a result. In 60 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for DVA just turned positive on October 05, 2026. Looking at past instances where DVA's MACD turned positive, the stock continued to rise in 25 of 41 cases over the following month. The odds of a continued upward trend are 61%.
The 10-day moving average for DVA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +1.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where DVA advanced for three days, in 242 of 353 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 144 of 237 cases where DVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
The Tickeron SMR rating for this company is 7 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. DVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-14.744) is normal, around the industry mean (204.137). P/E Ratio (14.259) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (0.436) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (0.968) is also within normal values, averaging (2.688).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of integrated dialysis services for patients suffering from chronic kidney failure
Industry HospitalNursingManagement